Numerous knowledge gaps exist regarding the care of female patients with cardiogenic shock, often because they have been consistently underrepresented in clinical trials, according to a new consensus ...
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...
After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient ...
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously ...
SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime ...
VitalStream is an FDA-cleared wireless, wearable monitor for continuous blood pressure and advanced hemodynamics. VitalStream tablet application. By simplifying the monitoring process and providing ...
The study questions whether it may be best to wait to implant a support device until arriving at a level 1 shock center.
WASHINGTON–A new initiative by The Society for Cardiovascular Angiography & Interventions (SCAI) proposes a new framework and call to action for managing cardiogenic shock (CS), establishing lactate ...
Some previous or preexisting cardiovascular conditions are associated with increased severity of COVID-19 among children, according to a study published online May 17 in JAMA Network Open. Women are ...
Etiometry, a leader in AI-driven clinical intelligence, today announced it has received FDA clearance (K254066) for the first-ever solution for automation of hospital-specific cardiogenic shock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results